Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1993 Mar 1;90(5):1922–1926. doi: 10.1073/pnas.90.5.1922

Development of potent gastrin-releasing peptide antagonists having a D-Pro-psi(CH2NH)-Phe-NH2 C terminus.

J J Leban 1, F C Kull Jr 1, A Landavazo 1, B Stockstill 1, J D McDermed 1
PMCID: PMC45992  PMID: 8446610

Abstract

Gastrin-releasing peptide (GRP) is a 27-amino acid neuroendocrine hormone that may play a role in the pathophysiology of small cell lung carcinoma. GRP and bombesin, a structurally related peptide, stimulate the growth of some cultured cell types. C-terminal GRP peptide analogs were developed that inhibited 6 nM bombesin-induced [3H]thymidine incorporation into quiescent murine Swiss 3T3 cells, which routinely produced a 6-fold stimulation over the basal extent of incorporation. The peptides were also analyzed for their capacity to inhibit the binding of 50 pM 125I-labeled GRP to Swiss 3T3 cells. The combination of two chemical modifications, each antagonistic in itself, led to the creation of antagonists with orders of magnitude greater potency than either modification alone. (i) Antagonist analogs of the form -Leu26-psi(CH2NH)-Xaa27-NH2 [where Xaa is Leu, norleucine (Nle), or Phe; residues numbered after GRP], similar to those introduced by Coy and coworkers [for review, see Jensen, R. T. & Coy, D. H. (1991) Trends Pharmacol. Sci. 12, 13-19], were found to have nanomolar potencies. (ii) We found that an octapeptide C-terminal GRP analog having D-Pro adjacent to the C-terminal amino acid amide was antagonistic, with a potency of 40 nM. By combining both modifications, specific analogs were found with potencies > 1000-fold greater than our lead structure--[(4'-hydroxy)-3-phenylpropanoyl]-Pro-Arg-Gly-Asn-His-Tr p-Ala-Val - Gly-His-Leu-psi(CH2NH)-Nle-NH2--and greater than any antagonist previously reported. The analogs [(4'-hydroxy)-3-phenylpropanoyl]-His-Trp-Ala-Val-D-Ala-His-D-Pro- psi(CH2NH)-Phe-NH2 and 1-naphthoyl-His-Trp-Ala-Val-D-Ala-His-D-Pro-psi(CH2NH)-Phe-NH2 antagonized [3H]thymidine incorporation with IC50 values of approximately 0.3 nM and inhibited the binding of 125I-labeled GRP with IC50 values of approximately 1 pM. These peptides may be of use in the study of the physiology of GRP.

Full text

PDF
1922

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Battey J., Wada E. Two distinct receptor subtypes for mammalian bombesin-like peptides. Trends Neurosci. 1991 Dec;14(12):524–528. doi: 10.1016/0166-2236(91)90005-f. [DOI] [PubMed] [Google Scholar]
  2. Carney D. N., Cuttitta F., Moody T. W., Minna J. D. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res. 1987 Feb 1;47(3):821–825. [PubMed] [Google Scholar]
  3. Coy D. H., Heinz-Erian P., Jiang N. Y., Sasaki Y., Taylor J., Moreau J. P., Wolfrey W. T., Gardner J. D., Jensen R. T. Probing peptide backbone function in bombesin. A reduced peptide bond analogue with potent and specific receptor antagonist activity. J Biol Chem. 1988 Apr 15;263(11):5056–5060. [PubMed] [Google Scholar]
  4. Coy D. H., Taylor J. E., Jiang N. Y., Kim S. H., Wang L. H., Huang S. C., Moreau J. P., Gardner J. D., Jensen R. T. Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity. J Biol Chem. 1989 Sep 5;264(25):14691–14697. [PubMed] [Google Scholar]
  5. Cuttitta F., Carney D. N., Mulshine J., Moody T. W., Fedorko J., Fischler A., Minna J. D. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. 1985 Aug 29-Sep 4Nature. 316(6031):823–826. doi: 10.1038/316823a0. [DOI] [PubMed] [Google Scholar]
  6. Folkers K., Feng D. M., Asano N., Håkanson R., Weisenfeld-Hallin Z., Leander S. Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4833–4835. doi: 10.1073/pnas.87.12.4833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Folkers K., Hörig J., Rosell S., Björkroth U. Chemical design of antagonists of substance P. Acta Physiol Scand. 1981 Apr;111(4):505–506. doi: 10.1111/j.1748-1716.1981.tb06771.x. [DOI] [PubMed] [Google Scholar]
  8. Heimbrook D. C., Saari W. S., Balishin N. L., Friedman A., Moore K. S., Reimen M. W., Kiefer D. M., Rotberg N. S., Wallen J. W., Oliff A. Carboxyl-terminal modification of a gastrin releasing peptide derivative generates potent antagonists. J Biol Chem. 1989 Jul 5;264(19):11258–11262. [PubMed] [Google Scholar]
  9. Jensen R. T., Coy D. H. Progress in the development of potent bombesin receptor antagonists. Trends Pharmacol Sci. 1991 Jan;12(1):13–19. doi: 10.1016/0165-6147(91)90483-9. [DOI] [PubMed] [Google Scholar]
  10. Jensen R. T., Moody T., Pert C., Rivier J. E., Gardner J. D. Interaction of bombesin and litorin with specific membrane receptors on pancreatic acinar cells. Proc Natl Acad Sci U S A. 1978 Dec;75(12):6139–6143. doi: 10.1073/pnas.75.12.6139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kull F. C., Jr, Leban J. J., Landavazo A., Stewart K. D., Stockstill B., McDermed J. D. Conveyance of partial agonism/antagonism to bombesin/gastrin-releasing peptide analogues on Swiss 3T3 cells by a carboxyl-terminal leucine insertion. J Biol Chem. 1992 Oct 15;267(29):21132–21138. [PubMed] [Google Scholar]
  12. Mahmoud S., Staley J., Taylor J., Bogden A., Moreau J. P., Coy D., Avis I., Cuttitta F., Mulshine J. L., Moody T. W. [Psi 13,14] bombesin analogues inhibit growth of small cell lung cancerin vitro and in vivo. Cancer Res. 1991 Apr 1;51(7):1798–1802. [PubMed] [Google Scholar]
  13. Maruno K., Yamaguchi K., Abe K., Suzuki M., Saijo N., Mishima Y., Yanaihara N., Shimosato Y. Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma. Cancer Res. 1989 Feb 1;49(3):629–632. [PubMed] [Google Scholar]
  14. Millar J. B., Rozengurt E. Arachidonic acid release by bombesin. A novel postreceptor target for heterologous mitogenic desensitization. J Biol Chem. 1990 Nov 15;265(32):19973–19979. [PubMed] [Google Scholar]
  15. Moody T. W., Pert C. B., Gazdar A. F., Carney D. N., Minna J. D. High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science. 1981 Dec 11;214(4526):1246–1248. doi: 10.1126/science.6272398. [DOI] [PubMed] [Google Scholar]
  16. Narayan S., Guo Y. S., Townsend C. M., Jr, Singh P. Specific binding and growth effects of bombesin-related peptides on mouse colon cancer cells in vitro. Cancer Res. 1990 Nov 1;50(21):6772–6778. [PubMed] [Google Scholar]
  17. Rivier J. E., Brown M. R. Bombesin, bombesin analogues, and related peptides: effects on thermoregulation. Biochemistry. 1978 May 2;17(9):1766–1771. doi: 10.1021/bi00602a030. [DOI] [PubMed] [Google Scholar]
  18. Rozengurt E. Early signals in the mitogenic response. Science. 1986 Oct 10;234(4773):161–166. doi: 10.1126/science.3018928. [DOI] [PubMed] [Google Scholar]
  19. Rozengurt E., Sinnett-Smith J. Bombesin stimulation of DNA synthesis and cell division in cultures of Swiss 3T3 cells. Proc Natl Acad Sci U S A. 1983 May;80(10):2936–2940. doi: 10.1073/pnas.80.10.2936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Saeed Z. A., Huang S. C., Coy D. H., Jiang N. Y., Heinz-Erian P., Mantey S., Gardner J. D., Jensen R. T. Effect of substitutions in position 12 of bombesin on antagonist activity. Peptides. 1989 May-Jun;10(3):597–603. doi: 10.1016/0196-9781(89)90149-6. [DOI] [PubMed] [Google Scholar]
  21. Sakakibara S., Shimonishi Y., Kishida Y., Okada M., Sugihara H. Use of anhydrous hydrogen fluoride in peptide synthesis. I. Behavior of various protective groups in anhydrous hydrogen fluoride. Bull Chem Soc Jpn. 1967 Sep;40(9):2164–2167. doi: 10.1246/bcsj.40.2164. [DOI] [PubMed] [Google Scholar]
  22. Sasaki Y., Murphy W. A., Heiman M. L., Lance V. A., Coy D. H. Solid-phase synthesis and biological properties of psi [CH2NH] pseudopeptide analogues of a highly potent somatostatin octapeptide. J Med Chem. 1987 Jul;30(7):1162–1166. doi: 10.1021/jm00390a008. [DOI] [PubMed] [Google Scholar]
  23. Singh P., Guo Y. S., Kull F. C., Leban J. J. A novel bombesin receptor antagonist (2258U89), potently inhibits bombesin evoked release of gastrointestinal hormones from rats and dogs, in vitro and in vivo. Regul Pept. 1992 Jul 2;40(1):75–86. doi: 10.1016/0167-0115(92)90085-9. [DOI] [PubMed] [Google Scholar]
  24. Wang L. H., Coy D. H., Taylor J. E., Jiang N. Y., Kim S. H., Moreau J. P., Huang S. C., Mantey S. A., Frucht H., Jensen R. T. Desmethionine alkylamide bombesin analogues: a new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells. Biochemistry. 1990 Jan 23;29(3):616–622. doi: 10.1021/bi00455a004. [DOI] [PubMed] [Google Scholar]
  25. Wang L. H., Coy D. H., Taylor J. E., Jiang N. Y., Moreau J. P., Huang S. C., Frucht H., Haffar B. M., Jensen R. T. des-Met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists, or agonists. J Biol Chem. 1990 Sep 15;265(26):15695–15703. [PubMed] [Google Scholar]
  26. Willey J. C., Lechner J. F., Harris C. C. Bombesin and the C-terminal tetradecapeptide of gastrin-releasing peptide are growth factors for normal human bronchial epithelial cells. Exp Cell Res. 1984 Jul;153(1):245–248. doi: 10.1016/0014-4827(84)90466-x. [DOI] [PubMed] [Google Scholar]
  27. Woll P. J., Rozengurt E. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc Natl Acad Sci U S A. 1988 Mar;85(6):1859–1863. doi: 10.1073/pnas.85.6.1859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wood S. M., Wood J. R., Ghatei M. A., Lee Y. C., O'Shaughnessy D., Bloom S. R. Bombesin, somatostatin and neurotensin-like immunoreactivity in bronchial carcinoma. J Clin Endocrinol Metab. 1981 Dec;53(6):1310–1312. doi: 10.1210/jcem-53-6-1310. [DOI] [PubMed] [Google Scholar]
  29. Yamaguchi K., Abe K., Kameya T., Adachi I., Taguchi S., Otsubo K., Yanaihara N. Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. Cancer Res. 1983 Aug;43(8):3932–3939. [PubMed] [Google Scholar]
  30. Zachary I., Rozengurt E. High-affinity receptors for peptides of the bombesin family in Swiss 3T3 cells. Proc Natl Acad Sci U S A. 1985 Nov;82(22):7616–7620. doi: 10.1073/pnas.82.22.7616. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES